Wird geladen...
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney,...
Gespeichert in:
| Veröffentlicht in: | Korean Circ J |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
The Korean Society of Cardiology
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8112180/ https://ncbi.nlm.nih.gov/pubmed/33975387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4070/kcj.2021.0070 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|